NIAID Site Search

NIH strategic plan to develop medical countermeasures against possible terrorist attacks involving radioactive materials.

Last Reviewed: December 5, 2019

This report outlines the ethical considerations for zika virus human challenge trials and provides recommendations.

Last Reviewed: November 26, 2019

HIV/AIDS pathogenesis & strategies for therapy & vaccine. Structure-function relationships in envelope glycoproteins can identify conserved functional regions & elucidate immune evasion, supporting VPS efforts to engineer HIV-neutralizing antibodies with improved potency & breadth. We combine immunology & virology with post-genomic technologies & pre-clinical in vivo studies in nonhuman primates.

Last Reviewed: September 28, 2022

A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental

Published: May 9, 2019

Findings explain why some people with COVID-19 develop severe disease and may provide the first molecular explanation for why more men than women die from COVID-19.

Published: September 24, 2020

A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum people. Researchers will measure the development and durability of antibodies against SARS-CoV-2, the virus that causes COVID-19, in people vaccinated during pregnancy or the first two postpartum months. Researchers also will assess vaccine safety and evaluate the transfer of vaccine-induced antibodies to infants across the placenta and through breast milk.

Published: June 23, 2021

An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. COVAXIN was developed and is manufactured

Published: June 29, 2021

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a

Published: August 27, 2021

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries. The Imbokodo primary

Published: August 31, 2021

In a recent NIH study, a long-acting injectable form of HIV prevention outperformed a daily pill.

Published: July 7, 2020

Two NIAID Phase 3 clinical trials testing experimental monoclonal antibodies are enrolling healthy adults at clinical trial sites in the United States.

Published: August 10, 2020

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes. These

Published: October 18, 2021

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Published: December 9, 2021

An experimental approach to enhancing a standard cat allergen immunotherapy, often called allergy shots, made it more effective and faster acting, and the benefits persisted for a year after treatment ended.

Published: October 11, 2022

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods. The investigators also aim to define the activity levels of asthma-associated gene networks that correspond to specific

Published: June 2, 2022

Dr. Auchincloss served as NIAID Principal Deputy Director from 2006 to 2024. He stepped into additional leadership roles, assuming the responsibilities of NIAID Division of Intramural Research Acting Director from 2014 to 2015 and NIAID Acting Director from 2022 to 2023.

Last Reviewed: October 3, 2024

Immunologic studies of human B cells in HIV and other infectious and non-infectious diseases

Last Reviewed: October 7, 2022

Sample application from Jose M. Galarza, Ph.D., for Small Business Technology Transfer (STTR) grant (R43).

Last Reviewed: November 25, 2022

A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary

Published: April 23, 2021

The HIV/AIDS: Antiretroviral Drugs module is part of the Pathogens in Augmented Reality (PathogenAR) mobile app. Acquired immunodeficiency syndrome (AIDS) is the most severe phase of infection with human immunodeficiency virus (HIV). There is no effective cure for HIV. However, by taking a combination of antiretroviral drugs, people with HIV can now live long and healthy lives. Antiretroviral

Last Reviewed: February 3, 2021

NIAID has awarded $2.5 million in grants to 12 institutes around the world to support research on bacteriophage therapy.

Published: March 11, 2021

Through collaboration within the HHS, including NIH, NIAID, and BARDA, the Antiviral Program for Pandemics will respond to the urgent need for antivirals to treat COVID-19.

Published: June 17, 2021

The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV.

Published: August 17, 2021

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a NIH clinical trial to test potential new treatment for the disease.

Published: August 4, 2020

A NIH study to determine the rate of novel coronavirus infection in children and family members in the United States has begun enrolling participants.

Published: May 4, 2020